[email protected].com +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies

November 2016 | 21 pages | ID: B3232588A37EN
La Merie Publishing

US$ 225.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
BCMA-Targeted Immunotherapeutics in:

October 2016 R&D and Business Tracker for Bispecific Antibodies

This pdf report contains information about Bispecific Antibodies released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.

Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted immunotherapeutics, the profile of German technology company Pieris Pharmaceuticals and the bispecific technology profile of FIT-Ig from EpiMab.

The October 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;
  • T-Cell redirecting bispecific cancer antibodies
  • NK cell redirecting bispecific cancer antibodies
  • Bispecific immuno-oncology antibodies
  • Bispecific tumor antigens targeted cancer antibodies
  • Bispecific antibodies for inflammatory & autoimmune diseases
  • Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases
The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker
  • Pipeline changes
  • Regulatory news
  • Technology validations
  • Manufacturing news
Business Tracker for:
  • Company updates
  • Collaboration
  • Licensing
  • Merger & acquisitions
  • Financing
Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Technology Profile: FIT-Ig

Featured Company Profile: Pieris Pharmaceuticals

Featured Target or Technology Pipeline: BCMA-Targeted Immunotherapeutics

BCMA-Targeted Immunotherapeutics include:
  • Autologous & allogeneic T-Cells
  • Bispecific tumor-targeted antibodies & T-cells
  • Bispecific T-Cell and NK-Cell redirecting antibodies
  • Antibody-Drug Conjugates
Information about the BCMA-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

Methodology:

Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Customized Update Service:

The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.


More Publications